Meeting
2013 ASCO Annual Meeting
Correlation of chemotherapy delivery and survival outcomes of follicular lymphoma in the immunchemotherapy era.
Authors
Kitsada Wudhikarn
University of Iowa Hospitals and Clinics, Iowa City, IA
Kitsada Wudhikarn , Anna M Button , Brian J. Smith , Thomas Matthew Habermann , Carrie A. Thompson , James Robert Cerhan , Brian K. Link
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8563)
DOI
10.1200/jco.2013.31.15_suppl.8563
Abstract #
8563
Poster Bd #
49B
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Evaluation of outcomes between rituximab-abbs and reference product rituximab in adult patients with newly diagnosed diffuse large B-cell lymphoma in a non-inferiority study.
First Author: Vivian Nguyen
Poster
2018 ASCO Annual Meeting
90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial.
First Author: Mariano Provencio-Pulla
Poster
2024 ASCO Annual Meeting
Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).
First Author: Colin Hardin
Poster
2024 ASCO Annual Meeting
Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).
First Author: Ruemu Ejedafeta Birhiray